At the time of writing, Cidara Therapeutics Inc [CDTX] stock is trading at $66.91, up 1.97%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CDTX shares have gain 7.66% over the last week, with a monthly amount glided 5.29%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Citizens JMP started tracking the stock with Mkt Outperform rating on March 12, 2025, and set its price target to $46. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $34 on December 13, 2024. Guggenheim initiated its recommendation with a Buy and recommended $33 as its price target on November 08, 2024. H.C. Wainwright upgraded its rating to Buy for this stock on August 14, 2024, but kept the price target unchanged to $24.
For the past year, the stock price of Cidara Therapeutics Inc fluctuated between $10.14 and $69.36. Currently, Wall Street analysts expect the stock to reach $69 within the next 12 months. Cidara Therapeutics Inc [NASDAQ: CDTX] shares were valued at $66.91 at the most recent close of the market. An investor can expect a potential return of 3.12% based on the average CDTX price forecast.
Analyzing the CDTX fundamentals
According to Cidara Therapeutics Inc [NASDAQ:CDTX], the company’s sales were 0.00M for trailing twelve months, which represents an -100.00% plunge. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.4 and Total Capital is -0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Cidara Therapeutics Inc [NASDAQ:CDTX] has a current ratio of 16.45. Also, the Quick Ratio is 16.45, while the Cash Ratio stands at 15.8.
Transactions by insiders
Recent insider trading involved Davarpanah Nicole Negar, Chief Medical Officer, that happened on Sep 11 ’25 when 474.0 shares were sold. Director, RA CAPITAL MANAGEMENT, L.P. completed a deal on Jun 26 ’25 to buy 2.27 million shares. Meanwhile, Director Mineo Chrysa bought 2270.0 shares on Jun 02 ’25.
